Biocon Limited announced that its subsidiary  company Syngene has entered into a research partnership with Bristol-Myers Squibb (NYSE: BMY).  Through this symbiotic global partnership, Biocon's Syngene will provide research and development (R&D) services for discovery and early drug development.  

Bristol-Myers Squibb will significantly increase the scope of its existing relationship with Biocon's Syngene to further develop integrated capabilities in India in medicinal chemistry, biology, drug metabolism, and pharmaceutical development. Under the terms of the agreement, Syngene  will partner with Bristol-Myers Squibb through a dedicated research facility at Biocon Park, Bangalore, which is planned to ultimately house more than 400 scientists to help advance Bristol-Myers Squibb's discovery and early drug development.  

Leveraging the current global demand for bio-partnering, this alliance aims to provide cost-effective growth and access to top scientific talent in India.

Related Items:

---

Be first to comment this article

Only registered users can write comments.
Please login or register.